Table 7.
Various HPLC methods for the detection of ACV (“N.A”: No data applicable or available).
| Methods | Operating Wavelength (nm) | Linear Range (μg/mL) | LOD (μg/mL) |
Samples | Recovery% | References |
|---|---|---|---|---|---|---|
| HPLC-VIS | 254 | 0.02–4 | 0.01 | plasma samples | 94.4–104.3 | [62] |
| HPLC-VIS | 254 | 0.010–2.560 | 0.01 | ACV in human serum | 90 ± 8% | [63] |
| HPLC-VIS | 254 | 0.25–100 | 2.5 | Plasma and amniotic fluid samples | >80% | [64] |
| HPLC-FLD | 260 | 100–20,000 | 33 | Plasma from pediatric oncology patients | 101% | [65] |
| HPLC-FLD, LC-HESI-MS/MS |
N.A | 0.1–1.5 | 0.05, 0.002 | equine plasma and body fluids | 98.8–99.3, 95.4–99.9 |
[66] |
| HPLC-PDA | 350 | 50–500 | N.A | ACV (ACV Hospira®) | N.A | [67] |
| HPLC-DAD | N.A | 100–1000 | 20 | ACV raw material | 99.2–101.6 | [68] |
| HPLC-UV | 254 | 35–70 | 0.048 | ACV in the vitreous humor | 98.18–99.64 | [69] |
| HPLC-UV | 255 | 0.1–5.0 | N.A | ACV in plasma samples | 91.37–98.98 | [70] |
| HPLC-UV | 254 | 0.001–5 | 0.0I | a pharmacokinetic linearity study in dogs. | 88.2–92.9 | [71] |
| a YMC-Triart C18 | 252.0 | 8–12 | 0.27 | Aciclovir Cream | 99. 6–100.6 | [72] |
a A reverse phase chromatographic.